rethinkTHC Search
Menu
Study breakdown

Adding Medical Cannabis to Opioids Reduced Pain in Hospice Patients With Few Side Effects

ObservationalPreliminary evidence
The takeaway

Hospice inpatients receiving standardized medical cannabis alongside scheduled opioids showed statistically significant pain reduction over the treatment period, with only 4.5% experiencing minor, reversible adverse events.

Hospice and palliative care physicians; patients and families exploring pain management options for end-of-life care.

Statistically significant pain reduction (p = .0029) with 4.5% minor adverse event rate

What the researchers found

The combination of medical cannabis (CBD-dominant formulation) and scheduled opioids showed a statistically significant longitudinal reduction in pain intensity (p = .0029). A non-significant trend toward lower opioid doses was observed. Well-being, appetite, nausea, and respiratory function showed non-significant changes. Only 3 of 66 patients (4.5%) had minor, reversible adverse events. No serious or life-threatening events occurred.

Why it matters

Pain management in end-of-life care often requires escalating opioid doses with increasing side effects. Adding a CBD-dominant cannabis formulation achieved significant additional pain relief without serious adverse events, potentially allowing patients to maintain comfort with lower opioid-related toxicity.

The numbers in context

66 inpatients assessed over 996 treatment days. Average age: 68.2 years, 90.9% White. Cancer was most common diagnosis. Significant pain reduction: p = .0029. Adverse events: 3 patients (4.5%), all minor and reversible. Cannabis doses: 40 mg CBD/1.5 mg THC or 80 mg CBD/3 mg THC.

How the study worked

Single-arm study of 66 hospice inpatients using scheduled oral, parenteral, or transdermal opioids. Patients received standardized oral medical cannabis: 40 mg CBD/1.5 mg THC or 80 mg CBD/3 mg THC. Outcomes assessed over 996 treatment days using the Mann-Whitney test and longitudinal mixed effects regression.

What this study cannot tell us

Single-arm design without placebo control means the placebo effect and natural disease progression cannot be separated from treatment effects. The predominantly White, cancer-diagnosis sample limits generalizability. The CBD-dominant formulation may not represent all cannabis products used in palliative settings.

How to read the evidence

Preliminary: significant pain findings in a clinical population, but single-arm design without placebo control and limited demographic diversity.

When this study was published

2024 study.

The bigger picture

Hospice care is one of the most ethically straightforward settings for cannabis research -- the priority is comfort, not long-term safety concerns. These preliminary results support the rationale for cannabis as a complement to opioids in end-of-life care, where quality of life during remaining time is the primary goal.

Questions still open

  • Would a controlled trial confirm these findings against placebo? Do different cannabis ratios (higher THC) provide greater or lesser pain benefit in hospice patients? Can cannabis reduce the opioid dose enough to meaningfully reduce opioid side effects?

Common questions

What cannabis formulation was used?
Patients received standardized oral medical cannabis with either 40 mg CBD/1.5 mg THC or 80 mg CBD/3 mg THC. This is a CBD-dominant formulation, meaning the effects are primarily attributed to CBD rather than psychoactive THC.
Did cannabis replace opioids?
No, cannabis was added as a complement to existing opioid therapy, not as a replacement. There was a non-significant trend toward lower opioid doses over time, but the study was not designed or powered to demonstrate opioid reduction.

Read the original research

Medical Marijuana for Pain Management in Hospice Care as a Complementary Approach to Scheduled Opioids: A Single Arm Study.

The American journal of hospice & palliative care, 41(9), 1002-1010

Citation

Zanker, Theodore; Sacco, Joseph; Prota, James; Palma, Michelle; Viola Lee, Kyoung A; Wang, Ruixiao Rachel; Liang, Yixuan; Cunningham, James; Mackary, Mona; Ovchinnikova, Polina. (2024). Medical Marijuana for Pain Management in Hospice Care as a Complementary Approach to Scheduled Opioids: A Single Arm Study.. The American journal of hospice & palliative care, 41(9), 1002-1010. https://doi.org/10.1177/10499091231213359

Explore the wider topic